{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:35:05Z","timestamp":1746322505752,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The coexistence of primary hyperparathyroidism and papillary thyroid carcinoma (PTC) is common and may be associative with more aggressive PTC, with higher rates of extrathyroidal\u00a0extension and multicentricity. However, it is unclear whether secondary hyperparathyroidism (SHPT) is associated with more invasive PTC in terms of morbidity, tumor pathological characteristics, and prognosis.\u00a0The aim of this study was to evaluate the rate and tumor characteristics of PTC in patients with SHPT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 531\u00a0patients\u00a0diagnosed with SHPT who underwent\u00a0surgery\u00a0from August 2013 to December 2018 at the First Affiliated Hospital of Zhejiang University were evaluated retrospectively. Patient demographics, surgical records, and follow-up information were recorded and analyzed. Control subjects were matched to the enrolled patients in a 1:4 ratio in terms of age, sex and pathological subtype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 531 patients with SHPT who underwent surgery, 34 had coexisting PTC and PTC\u2009+\u2009SHPT (6.4%). The mean tumor diameter in the PTC\u2009+\u2009SHPT group was smaller than that in the PTC group (5.57\u00a0mm vs 9.00\u00a0mm, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The proportion of papillary thyroid micro-carcinoma in the PTC\u2009+\u2009SHPT group was significantly higher than that in the PTC group (29 [85.29%] vs. 86[63.24%], <jats:italic>p<\/jats:italic>\u2009=\u20090.014). There were no\u00a0statistically\u00a0significant\u00a0differences\u00a0between groups in terms of tumor multicentricity (15 [44.12%] vs 39 [28.68%], <jats:italic>p<\/jats:italic>\u2009=\u20090.066), tumor bilaterality (9 [26.47%] vs. 29 [21.32%], <jats:italic>p<\/jats:italic>\u2009=\u20090.499), tumor extrathyroidal extension (2 [5.88%] vs. 19 [13.97%], <jats:italic>p<\/jats:italic>\u2009=\u20090.255), or lymph node (LN) metastasis rate (12 [35.29%] vs. 49 [36.03%], <jats:italic>p<\/jats:italic>\u2009=\u20091.000). However, the PTC\u2009+\u2009SHPT and PTC groups were significantly different in terms of contralateral thyroidectomy (10 [29.41%] vs. 70 [51.47%], <jats:italic>p<\/jats:italic>\u2009=\u20090.023) and lymph node dissection (22 [64.71%] vs. 125 [91.91%], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).There was no significant difference between the PTC\u2009+\u2009SHPT and PTC groups in terms of prognostic staging (33 [97.06%] vs. 122 [89.71%], <jats:italic>p<\/jats:italic>\u2009=\u20090.309) or recurrence (mean follow-up time: 36\u00a0months vs. 39\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.33).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence of PTC is high in patients with SHPT; compared with PTC in the general population, most papillary thyroid carcinomas with SHPT are occult thyroid carcinomas and present no significant difference in terms of tumor pathological features and prognostic staging. It is necessary for surgeons to perform more adequate preoperative examination and be more careful during surgery to avoid missing the coexistence of PTC in patients with SHPT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12893-021-01330-z","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:03:19Z","timestamp":1630929799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Coexistence of papillary thyroid carcinoma in secondary hyperparathyroidism"],"prefix":"10.1186","volume":"21","author":[{"given":"Junhao","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuochao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haohao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6470-9017","authenticated-orcid":false,"given":"Lisong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"4","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/bjs.9661","volume":"102","author":"R Schneider","year":"2015","unstructured":"Schneider R, Bartsch DK. Role of surgery in the treatment of renal secondary hyperparathyroidism. Br J Surg. 2015;102(4):289\u201390.","journal-title":"Br J Surg"},{"issue":"1","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12882-016-0421-5","volume":"18","author":"LY Ho","year":"2017","unstructured":"Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, Lo MW, Lo KY, Mak SK, Wong AK. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):12.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1330_CR3","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.1038\/s41598-018-26142-9","volume":"8","author":"X Sun","year":"2018","unstructured":"Sun X, Zhang X, Lu Y, Zhang L, Yang M. Risk factors for severe hypocalcemia after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Sci Rep. 2018;8(1):7743.","journal-title":"Sci Rep"},{"issue":"1","key":"1330_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ckj\/sfx125","volume":"11","author":"L Pereira","year":"2018","unstructured":"Pereira L, Meng C, Marques D, Frazao JM. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J. 2018;11(1):80\u20138.","journal-title":"Clin Kidney J"},{"issue":"1","key":"1330_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/0929867324666170509125840","volume":"25","author":"J Aaseth","year":"2018","unstructured":"Aaseth J, Bjorke-Monsen AL. Lanthanum carbonate\u2014a new phosphate binding drug in advanced renal failure. Curr Med Chem. 2018;25(1):113\u20137.","journal-title":"Curr Med Chem"},{"key":"1330_CR6","doi-asserted-by":"crossref","unstructured":"Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1\u201359. Kidney international supplements 2017, 7(3):e1.","DOI":"10.1016\/j.kisu.2017.10.001"},{"issue":"4","key":"1330_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T. Evocalcet study g: Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818\u201325.","journal-title":"Kidney Int"},{"key":"1330_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41199-016-0021-x","volume":"2","author":"LD Hahn","year":"2017","unstructured":"Hahn LD, Kunder CA, Chen MM, Orloff LA, Desser TS. Indolent thyroid cancer: knowns and unknowns. Cancers Head Neck. 2017;2:1.","journal-title":"Cancers Head Neck"},{"issue":"5","key":"1330_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MED.0000000000000359","volume":"24","author":"BR Roman","year":"2017","unstructured":"Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017;24(5):332\u20136.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"1330_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/oxfordjournals.aje.a114668","volume":"126","author":"AF Kantor","year":"1987","unstructured":"Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumenti JF Jr. Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol. 1987;126(3):370\u20136.","journal-title":"Am J Epidemiol"},{"key":"1330_CR11","first-page":"S1","volume":"113","author":"K Disease","year":"2009","unstructured":"Disease K. Improving Global Outcomes CKDMBDWG: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-130.","journal-title":"Kidney Int Suppl"},{"issue":"11","key":"1330_CR12","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167\u2013214.","journal-title":"Thyroid"},{"issue":"9","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1245\/s10434-016-5225-0","volume":"23","author":"SK Kim","year":"2016","unstructured":"Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, Kim JS. Predictive factors for lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 2016;23(9):2866\u201373.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1330_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1210\/edrv-17-1-45","volume":"17","author":"EM Kaptein","year":"1996","unstructured":"Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17(1):45\u201363.","journal-title":"Endocr Rev"},{"issue":"2","key":"1330_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000013314","volume":"18","author":"S Vamvakas","year":"1998","unstructured":"Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved -editorial. Am J Nephrol. 1998;18(2):89\u201395.","journal-title":"Am J Nephrol"},{"issue":"3","key":"1330_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ejim.2014.01.001","volume":"25","author":"SY Lin","year":"2014","unstructured":"Lin SY, Lin WM, Lin CL, Yang TY, Sung FC, Wang YH, Kao CH. The relationship between secondary hyperparathyroidism and thyroid cancer in end stage renal disease: a population based cohort study. Eur J Intern Med. 2014;25(3):276\u201380.","journal-title":"Eur J Intern Med"},{"issue":"9","key":"1330_CR17","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s00268-005-7859-0","volume":"29","author":"D Seehofer","year":"2005","unstructured":"Seehofer D, Rayes N, Klupp J, Nussler NC, Ulrich F, Graef KJ, Schindler R, Steinmuller T, Frei U, Neuhaus P. Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature. World J Surg. 2005;29(9):1180\u20134.","journal-title":"World J Surg"},{"issue":"6","key":"1330_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1330_CR19","doi-asserted-by":"crossref","unstructured":"Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE, Pathak KA, Bureau Y, Rachinsky I, Badreddine M et al: Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 2019.","DOI":"10.1089\/thy.2018.0775"},{"issue":"11","key":"1330_CR20","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40618-018-0865-5","volume":"41","author":"G Sapuppo","year":"2018","unstructured":"Sapuppo G, Tavarelli M, Russo M, Malandrino P, Belfiore A, Vigneri R, Pellegriti G. Lymph node location is a risk factor for papillary thyroid cancer-related death. J Endocrinol Invest. 2018;41(11):1349\u201353.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1330_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-016-9398-4","volume":"17","author":"A Ieni","year":"2016","unstructured":"Ieni A, Barresi V, Cardia R, Licata L, Di Bari F, Benvenga S, Tuccari G. The micropapillary\/hobnail variant of papillary thyroid carcinoma: a review of series described in the literature compared to a series from one southern Italy pathology institution. Rev Endocr Metab Disord. 2016;17(4):521\u20137.","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"1330_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S2213-8587(16)30180-2","volume":"4","author":"S Leboulleux","year":"2016","unstructured":"Leboulleux S, Tuttle RM, Pacini F, Schlumberger M. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 2016;4(11):933\u201342.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-021-01330-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-021-01330-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-021-01330-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:08:25Z","timestamp":1630930105000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-021-01330-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1186\/s12893-021-01330-z","relation":{},"ISSN":["1471-2482"],"issn-type":[{"type":"electronic","value":"1471-2482"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"27 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}